OakChart

Fulcrum Therapeutics Inc

FULCHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

3.74+0.02 (0.54%)
2026-11-12 00:53 CET
Market cap
283.83 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-85.00 USD m
Free cash flow, TTM
-66.14 USD m
EPS diluted, TTM
-1.21
P/E
-
Compare

Price

FULC against its 20, 50 and 200-day averages
2050200miss
4.006.008.0016.4M32.8MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26FULCclose 3.7420-day 3.7050-day 3.74200-day 5.593.7452w low

76.2% under the 52-week high of 15.74 on 8 Dec 2025. 52-week low 2.83 on 2 Jun 2026. Last 15 sessions, 4.5% high to low

Volume 0.59× normal · the line is the 50-bar volume average

Profile

FULC
52-week range, 7% of the way up
2.8315.74

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015, and is headquartered in Cambridge, MA.

IndexRUT
Employees55
IPOJul 18, 2019
Beta2.77
ATR, 14d0.07
Rel volume0.59
Short float8.74%
Insider own3.37%
Inst own101.67%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap285.36M
Enterprise Value-28.20M
Income-85.00M
Sales0.00M
Book/sh4.07
Cash/sh4.18
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees55
IPOJul 18, 2019

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.92
P/C0.89
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio31.35
Current Ratio31.35
Debt/Eq0.02
LT Debt/Eq0.01
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.21
EPS next Y-0.06
EPS next Q-0.04
EPS this Y57.63%
EPS next Y89.00%
EPS next 5Y79.61%
EPS past 3/5Y21.49% 15.80%
Sales past 3/5Y- -
EPS Y/Y TTM0.04%
Sales Y/Y TTM-100.00%
EPS Q/Q-24.16%
Sales Q/Q-
EarningsAug 05
EPS/Sales Surpr.-33.07% -

Ownership

Insider Own3.37%
Insider Trans18.40%
Inst Own101.67%
Inst Trans-14.77%
ROA-30.75%
ROE-32.38%
ROIC-27.12%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA200.96%
SMA500.03%
SMA200-33.05%
Trades-

Technical

Shs Outstand76.29M
Shs Float73.73M
Short Float8.74%
Short Ratio4.33
Short Interest6.44M
52W High15.74 -76.24%
52W Low2.83 32.16%
Volatility1.93% 1.89%
ATR (14)0.07
RSI (14)52.45
Beta2.77
Rel Volume0.59
Avg Volume1.49M
Volume881,429

Performance

Perf Week-0.80%
Perf Month1.63%
Perf Quarter0.81%
Perf Half Y-48.41%
Perf YTD-66.93%
Perf Year-54.11%
Perf 3Y6.86%
Perf 5Y-79.54%
Perf 10Y-
Recom3.00
Target Price4.00
Prev Close3.72
Price3.74
Change %0.54%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Jun 03, 2026DowngradeJJP MorganOverweight → Underweight
Jun 02, 2026DowngradeTTruistBuy → Hold$4+7.0%
Jun 02, 2026DowngradeSStifelBuy → Hold$3-19.8%
Jun 02, 2026DowngradePPiper SandlerOverweight → Neutral$3-19.8%
Jun 02, 2026DowngradeLLeerink PartnersOutperform → Market Perform$4+7.0%
Jun 02, 2026DowngradeHH.C. WainwrightBuy → Neutral$3-19.8%
Jan 12, 2026InitiatedJJP MorganOverweight$20+434.8%
Nov 24, 2025InitiatedTTruistBuy
Jul 29, 2025UpgradeHH.C. WainwrightNeutral → Buy$4 → $12+220.9%
May 23, 2025UpgradeLLeerink PartnersMarket Perform → Outperform$12+220.9%

Peers

Mkt cap
TickerCompanyMkt cap
BHVNBiohaven Ltd2.29B
AXSMAxsome Therapeutics Inc7.85B
LTGOLatigo Biotherapeutics Inc896.37M
VNDAVanda Pharmaceuticals Inc250.95M
SPTXSeaport Therapeutics Inc1.14B
TNXPTonix Pharmaceuticals Holding Corp75.20M
RAPPRapport Therapeutics Inc1.60B
DWTXDogwood Therapeutics Inc45.11M
PRAXPraxis Precision Medicines Inc9.68B
XENEXenon Pharmaceuticals Inc4.14B

Insider trading

latest 14 of 16
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Greg Tourangeauformer officerSep 02 '26Proposed Sale3.8714,06254,420Sep 02 09:30 AM
TANG KEVIN10% OwnerJul 16 '26Buy3.56116,671415,3497,030,000Jul 20 09:10 PM
TANG KEVIN10% OwnerJul 17 '26Buy3.5250,945179,3267,080,945Jul 20 09:10 PM
TANG KEVIN10% OwnerJul 14 '26Buy3.57129,603462,9066,805,952Jul 15 07:50 PM
TANG KEVIN10% OwnerJul 15 '26Buy3.56107,377382,2626,913,329Jul 15 07:50 PM
TANG KEVIN10% OwnerJul 13 '26Buy3.5412,96645,9006,676,349Jul 15 07:50 PM
Ezekowitz AlanDirectorJun 26 '26Sale3.6518,00065,61410,927Jun 30 04:30 PM
ALAN EZEKOWITZDirectorJun 26 '26Proposed Sale3.6118,00064,980Jun 26 04:26 PM
Gould Robert JDirectorFeb 02 '26Sale10.7215,000160,857454,864Feb 04 04:10 PM
Gould Robert JDirectorJan 02 '26Sale11.8715,000178,089469,864Jan 06 04:30 PM
Oltmans Curtis GaleChief Legal OfficerDec 15 '25Sale12.923,45244,60010,252Dec 17 04:10 PM
CURTIS G OLTMANSOfficerDec 15 '25Proposed Sale13.003,45244,876Dec 15 04:32 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerDec 08 '25Sale13.984,175,13958,377,0216,053,960Dec 10 04:42 PM
RA Capital Healthcare Fund LP10% OwnerDec 08 '25Proposed Sale12.994,175,13954,235,056Dec 08 05:40 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
IBBiShares Biotechnology ETFAUM: 11.36B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
IWCiShares Micro-Cap ETFAUM: 1.22B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B

News

latest 14 of 196

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-05-0.342-0.257-0.3430.000.008
2026Q12026-04-27-0.250-0.294-0.2480.000.0011
2025Q42026-02-24-0.310-0.299-0.3090.000.0011
2025Q32025-10-29-0.310-0.294-0.3130.000.008
2025Q22025-07-29-0.280-0.290-0.2770.000.008
2025Q12025-05-01-0.280-0.294-0.2830.000.005
2024Q42025-02-25-0.310-0.282-0.3070.000.006
2024Q32024-11-13-0.350-0.396-0.3480.000.008
2024Q22024-07-310.870-0.4120.87180.0014.825
2024Q12024-05-13-0.430-0.438-0.4340.000.428
2023Q42024-02-27-0.400-0.426-0.4000.870.557
2023Q32023-11-07-0.390-0.441-0.3890.761.057
2023Q22023-08-03-0.380-0.454-0.3850.881.126
2023Q12023-05-15-0.410-0.463-0.4150.301.078
2022Q42023-03-09-0.500-0.490-0.5020.691.899
2022Q32022-11-08-0.510-0.612-0.5141.182.548

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-8.130-4.033-8.1300.000.00
2020FY-2.790-2.797-2.7938.825.69
2021FY-2.290-2.465-2.28619.1614.39
2022FY-2.440-2.414-2.4426.347.35
2023FY-1.590-1.640-1.5882.812.31
2024FY-0.160-0.148-0.15780.0080.47
2025FY-1.180-1.164-1.1800.000.00
2026FY--0.500--0.00
2027FY--0.055--0.00
2028FY--0.010---
2029FY--0.040---
2030FY--0.040---

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-09-091000.000.000.00
2026Q3S2026-08-054000.000.000.00
2026Q3S2026-07-015000.000.000.00
2026Q3S2026-06-036000.000.000.00
2026Q3S2026-05-087000.000.000.00
2026Q3S2026-04-276000.000.000.00
2026Q3S2026-02-246000.000.000.00
2026Q3S2025-11-116000.000.000.00
2026Q3S2025-11-106000.000.000.00
2026Q3S2025-11-096000.000.000.00
2026Q3S2025-11-086000.000.000.00
2026Q3S2025-11-076000.000.000.00
2026Q3S2025-11-066000.000.000.00
2026Q3S2025-11-055000.000.000.00

Estimate history

EPS, annual-1.087-1.677-8.13-2.793-2.286-2.442-1.588-0.157-1.182-1.2133
Period201720182019202020212022202320242025TTM
EPS, quarterly0.871-0.348-0.307-0.283-0.277-0.313-0.309-0.248-0.343
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0008.82319.1636.3422.8058000
Period201720182019202020212022202320242025TTM
Sales, quarterly8000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual23.3423.3422.65427.94240.62652.09961.91553.96866.57976.285
Period201720182019202020212022202320242025MRQ
Shares, quarterly62.25153.93953.96853.97954.09254.10866.57966.60876.285
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.0080.002.816.3419.168.820.000.00
Cost of Goods Sold Incl. D&A1.201.391.592.172.412.522.382.051.34
Gross Profit-1.20-1.3978.410.633.9316.656.44-2.05-1.34
Selling, General and Administrative Excl. Other85.4483.3898.24111.30116.0697.7078.0656.5732.15
Research and Development55.0454.7161.7971.8074.3767.1956.6643.4325.18
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-86.64-84.77-19.83-110.66-112.13-81.05-71.61-58.63-33.50
Interest Expense0.000.000.000.000.000.00---
Unusual Expense9.400.002.060.000.430.000.0025.590.00
Net Income Before Taxes-85.00-74.88-9.72-97.33-109.87-80.85-70.82-82.68-32.59
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-85.00-74.88-9.72-97.33-109.87-80.85-70.82-82.68-32.59
Net Income From Continuing Operations-85.00-74.88-9.72-97.33-109.87-80.85-70.82-82.68-32.59
Net Income-85.00-74.88-9.72-97.33-109.87-80.85-70.82-89.81-39.15
EPS (Recurring)-1.03-1.18-0.13-1.59-2.44-2.29-2.79-6.51-1.68
EPS (Basic, Before Extraordinaries)-1.21-1.18-0.16-1.59-2.44-2.29-2.79-8.13-1.68
EPS (Diluted)-1.21-1.18-0.16-1.59-2.44-2.29-2.79-8.13-1.68
EBITDA-85.44-83.38-18.24-108.49-109.72-78.54-69.23-56.57-32.15
Non-Operating Income (Expense)11.059.8912.1713.332.690.210.791.540.91
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense13.5612.4714.5514.8013.3511.077.354.222.16
Price To Sales Ratio--3.64147.5451.6532.6433.65--
Gross Margin--98.0122.5761.9486.8873.04--
Operating Margin---24.79-3,945.24-1,768.12-422.97-811.64--
Net Margin---12.16-3,470.05-1,732.43-421.89-802.66--
Shares Outstanding76.2966.5853.9761.9252.1040.6327.9422.6523.34
Market Capitalization283.83283.83253.51417.30378.93695.37321.59388.39407.30

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.220.340.350.300.300.350.370.40
Gross Profit-0.22-0.34-0.35-0.30-0.30-0.35-0.37-0.40
Selling, General and Administrative Excl. Other19.6921.8522.3521.5619.5220.0519.0622.66
Research and Development12.2313.7515.0714.0012.6913.0511.3414.24
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-19.91-22.19-22.69-21.86-19.82-20.40-19.43-23.06
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense9.400.000.000.000.000.000.002.06
Net Income Before Taxes-26.18-18.89-20.33-19.59-17.30-17.66-16.57-21.70
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-26.18-18.89-20.33-19.59-17.30-17.66-16.57-21.70
Net Income From Continuing Operations-26.18-18.89-20.33-19.59-17.30-17.66-16.57-21.70
Net Income-26.18-18.89-20.33-19.59-17.30-17.66-16.57-21.70
EPS (Recurring)-0.26-0.25-0.31-0.31-0.28-0.28-0.31-0.32
EPS (Basic, Before Extraordinaries)-0.34-0.25-0.31-0.31-0.28-0.28-0.31-0.35
EPS (Diluted)-0.34-0.25-0.31-0.31-0.28-0.28-0.31-0.35
EBITDA-19.69-21.85-22.35-21.56-19.52-20.05-19.06-22.66
Non-Operating Income (Expense)3.133.292.362.262.522.752.863.43
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.273.863.073.362.883.172.483.82
Price To Sales Ratio-----2.253.172.76
Shares Outstanding76.2966.6166.5854.1154.0953.9853.9753.94
Market Capitalization283.83510.82746.12497.64371.38155.46253.51222.77

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments352.31241.02236.22202.92218.16112.9196.7172.800.41
Short Term Receivables1.073.342.251.084.112.710.110.500.04
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets4.105.563.733.523.733.893.260.800.89
Total Current Assets357.48249.92242.20207.52226.00119.51100.0874.091.34
Net Property, Plant & Equipment7.079.5812.3915.977.378.409.2110.552.94
Total Investments and Advances1.201.201.091.091.091.091.091.090.00
Other Assets0.540.012.012.100.540.580.060.040.06
Total Assets366.28260.72257.69226.69235.00129.58110.4485.774.34
Short Term Debt Incl. Current Port. of LT Debt2.402.192.192.600.000.020.050.050.00
Accounts Payable1.591.162.763.644.794.082.191.261.67
Other Current Liabilities9.057.698.7310.4814.4122.639.902.921.11
Total Current Liabilities13.0511.0413.6816.7319.2026.7312.144.232.79
Long Term Debt4.046.448.6310.820.000.000.02139.7534.59
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.200.200.200.204.267.6711.125.460.23
Total Liabilities17.2817.6822.5027.7423.4634.4023.29149.4437.60
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity349.00243.03235.19198.94211.5495.1887.15-63.67-33.27
Total Shareholders Equity349.00243.03235.19198.94211.5495.1887.15-63.67-33.27
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity349.00243.03235.19198.94211.5495.1887.15-63.67-33.27
Total Liabilities & Stockholders Equity366.28260.72257.69226.69235.00129.58110.4485.774.34
Book Value Per Share5.244.503.803.825.213.413.85-2.73-1.43
Tangible Book Value Per Share5.244.503.803.825.213.413.85-2.73-1.43
Full-Time Employees55457689104737357-
Price to Book Ratio0.910.991.631.713.403.444.333.85-
Return on Assets-23.89-3.75-40.19-47.60-44.35-59.01-84.27-72.33-
Return on Equity-25.30-4.07-44.84-53.53-52.72-77.68-704.14--
Return on Invested Capital-21.21-3.90-39.92-52.38-38.22-74.40-94.84-42.83-1,737.07
Quick Ratio27.4022.6317.7112.4111.774.478.2417.520.48
Current Ratio27.4022.6317.7112.4111.774.478.2417.520.48

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-85.00-74.88-9.72-97.33-109.87-80.85-70.82-96.93-32.59
Depreciation1.251.391.592.172.412.522.382.051.34
Other Funds (Non Cash)16.109.5210.168.8113.5011.747.2844.072.16
Funds from Operations-67.66-63.982.03-86.35-93.96-66.59-61.16-50.81-29.08
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital1.883.91-4.25-4.61-3.09-11.897.5011.336.52
Cash from Operating Activities-65.78-60.06-2.22-90.97-97.05-78.48-53.66-39.48-22.56
Capital Expenditures-0.36-0.31-0.28-0.51-1.96-1.71-1.34-0.85-8.98
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.450.000.000.000.000.000.000.00-
Purchase or Sale of Investments-96.9531.0332.51-36.1814.38-127.96-55.800.000.00
Purchase of Investments-222.98-180.22-178.59-194.89-151.15-216.23-124.270.000.00
Sale Or Maturity of Investments126.03211.25211.10158.71165.5388.2868.470.000.00
Other Uses0.000.000.000.000.000.000.00-0.090.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-96.8730.7232.23-36.6912.41-129.67-57.14-0.94-8.98
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock168.74168.672.75118.1284.32186.5371.1864.39105.09
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock168.74168.672.75118.1284.32186.5371.1864.39105.09
Proceedsfrom Stock Options164.50164.500.00117.3480.80186.5371.1864.39105.09
Issuance or Reduction of Debt, Net0.000.000.000.000.00-0.02-0.05-0.04-0.07
Change in Long Term Debt0.000.000.000.000.00-0.020.00-0.04-0.07
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.00-0.020.00-0.04-0.07
Net Financing Active Other Cash Flow-0.330.000.000.000.000.000.000.000.00
Other Financing Activities Uses-0.330.000.000.000.000.000.000.000.00
Cash from Financing Activities168.41168.672.75118.1284.32186.5171.1364.34105.03
Net Change in Cash5.77139.3232.76-9.54-0.31-21.64-39.6623.9273.48
Free Cash Flow-66.14-60.38-2.50-91.47-99.01-80.19-55.00-40.34-31.54
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00--
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments318.84333.32352.31200.65214.11226.60
Short Term Receivables2.031.781.070.931.332.54
Inventories0.000.000.000.000.000.00
Other Current Assets1.983.584.104.283.933.41
Total Current Assets322.85338.67357.48205.86219.37232.56
Net Property, Plant & Equipment0.006.357.077.798.258.88
Total Investments and Advances1.091.201.201.201.211.20
Other Assets0.010.550.540.010.010.01
Total Assets323.95346.77366.28214.86228.84242.65
Short Term Debt Incl. Current Port. of LT Debt2.522.462.402.352.292.24
Accounts Payable3.422.451.592.861.751.51
Other Current Liabilities4.364.959.056.434.944.35
Total Current Liabilities10.309.8613.0511.638.988.10
Long Term Debt2.763.414.044.665.285.87
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.200.200.200.200.200.20
Total Liabilities13.2613.4717.2816.4914.4614.16
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity310.70333.30349.00198.37214.38228.49
Total Shareholders Equity310.70333.30349.00198.37214.38228.49
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity310.70333.30349.00198.37214.38228.49
Total Liabilities & Stockholders Equity323.95346.77366.28214.86228.84242.65
Book Value Per Share4.075.005.243.673.964.23
Tangible Book Value Per Share4.075.005.243.673.964.23
Full-Time Employees--55---
Price to Book Ratio0.911.463.082.321.630.64
Return on Assets-30.75-25.83-23.89-28.80-27.99-0.21
Return on Equity-32.38-27.10-25.30-31.21-30.00-0.23
Return on Invested Capital-8.35-5.61-5.76-9.65-7.87-7.53
Quick Ratio31.3534.3327.4017.7024.4228.71
Current Ratio31.3534.3327.4017.7024.4228.71

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-26.18-18.89-20.33-19.59-17.30-17.66
Depreciation0.220.340.350.350.340.35
Other Funds (Non Cash)7.553.092.682.771.792.27
Funds from Operations-18.42-15.46-17.30-16.48-15.16-15.03
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital2.38-3.290.512.291.34-0.22
Cash from Operating Activities-16.04-18.75-16.80-14.19-13.82-15.26
Capital Expenditures-0.11-0.01-0.16-0.09-0.070.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.450.000.000.000.000.00
Purchase or Sale of Investments13.44-128.20-0.8918.7014.00-0.78
Purchase of Investments-24.22-155.34-26.14-17.29-76.39-60.40
Sale Or Maturity of Investments37.6527.1425.2535.9990.3959.62
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities13.78-128.21-1.0518.6113.93-0.78
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.360.02168.300.060.300.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.360.02168.300.060.300.00
Proceedsfrom Stock Options0.000.00164.500.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.00-0.330.000.000.000.00
Other Financing Activities Uses0.00-0.330.000.000.000.00
Cash from Financing Activities0.36-0.31168.300.060.300.00
Net Change in Cash-1.90-147.27150.464.490.41-16.03
Free Cash Flow-16.15-18.76-16.96-14.28-13.88-15.26
Price to Free Cash Flow-----23.80

Revenue breakdown

Pharmaceutical Preparations2024: 80.00M
United States2024: 80.00M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-308.74%6.4M73.7M1.56M
2026-10-159.16%6.8M73.7M1.55M
2026-09-309.64%7.1M73.7M1.60M
2026-09-159.76%7.2M73.7M2.04M
2026-08-319.52%7.0M73.7M2.87M
2026-08-149.03%6.7M73.7M2.61M
2026-07-3110.26%6.6M64.6M2.49M
2026-07-1512.25%6.9M56.4M2.40M
2026-06-3011.38%6.4M56.4M2.28M
2026-06-159.79%5.5M56.4M1.77M
2026-05-2914.17%8.0M56.4M922.71K
2026-05-1513.82%7.8M56.4M1.06M
2026-04-3014.02%8.0M56.8M1.05M
2026-04-1513.30%7.6M56.8M1.04M
2026-03-3112.28%7.0M56.7M1.04M
2026-03-138.70%4.9M56.7M932.95K
2026-02-277.43%4.2M56.7M1.41M
2026-02-136.20%3.5M56.7M1.35M
2026-01-306.46%3.9M59.9M1.38M
2026-01-155.99%3.6M59.9M1.36M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.002.103.500.0019.3450.000.000.974-0.0380.000
call2.001.153.900.0021.8750.000.000.970-0.0490.000
call3.000.251.500.005.3800.000.000.880-0.0910.001
call4.000.002.150.010.84620.000.000.482-0.0270.002
call5.000.002.150.001.8380.000.000.192-0.0170.002
call6.000.001.750.002.0030.000.000.099-0.0110.001
call7.000.000.750.003.0180.000.000.136-0.0220.001
put1.000.002.150.000.0000.000.00-0.026-0.0380.000
put2.000.002.150.000.0000.000.00-0.030-0.0480.000
put3.000.002.150.0012.1660.000.00-0.144-0.0900.001
put4.000.002.450.508.5971.000.00-0.518-0.0270.002
put5.000.702.050.005.0650.000.00-0.808-0.0160.002
put6.001.703.100.006.1100.000.00-0.845-0.0190.001
put7.002.703.900.005.8760.000.00-0.864-0.0210.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-04EFFECTEffectiveness filing by commission orderSEC
2026-11-04424B3SEC
2026-11-03S-4/ASEC
2026-10-28SCHEDULE 13G/ASEC
2026-10-27SCHEDULE 13G/ASEC
2026-10-20S-4/ASEC
2026-10-08S-4/ASEC
2026-09-02144Filing for proposed sale of securities under Rule 144.SEC
2026-09-02S-4Registration statement for securities to be issued in business combination transactionsSEC
2026-08-17425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-08-17425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-08-17425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-08-178-KCurrent report2026-08-16SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13GSEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-108-KCurrent report2026-08-07SEC
2026-08-03SCHEDULE 13GSEC
2026-07-3010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-28SCHEDULE 13G/ASEC
2026-07-204Statement of changes in beneficial ownership of securities2026-07-16SEC
2026-07-17SCHEDULE 13GSEC
2026-07-15SCHEDULE 13G/ASEC
2026-07-154Statement of changes in beneficial ownership of securities2026-07-13SEC
2026-07-153Initial statement of beneficial ownership of securities2026-07-13SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-071.49M500
2026-060065.61K1
2026-050000
2026-040000
2026-030000
2026-0200160.86K1
2026-0100178.09K1
2025-120058.42M2
2025-1100165.50K1

Institutional holders

Manager% owned
Nantahala Capital Management, LLC16.43%
BlackRock, Inc.13.24%
EcoR1 Capital, LLC9.83%
TANG CAPITAL MANAGEMENT LLC9.79%
MONTANOVA CAPITAL, LLC5.52%
D. E. Shaw & Co., Inc.4.57%
CITADEL ADVISORS LLC4.06%
VANGUARD CAPITAL MANAGEMENT LLC4.05%
JANE STREET GROUP, LLC3.33%
STATE STREET CORP3.06%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND3.11%
iShares Russell 2000 ETF2.33%
BlackRock Advantage Small Cap Core Fund1.95%
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF1.21%
Fidelity Small Cap Index Fund0.97%
iShares Russell 2000 Value ETF0.85%
VANGUARD EXTENDED MARKET INDEX FUND0.83%
iShares Biotechnology ETF0.60%
VANGUARD RUSSELL 2000 INDEX FUND0.44%
Strategic Advisers U.S. Total Stock Fund0.38%

OakChart. FULC. Cached 15 minutes.